BRCA1 and ovarian cancer: Inhibiting PARP1 in HR-deficient cells, such as the BRCA1- or 2-mutant breast and ovarian cancers, leads to an accumulation of DNA damage from replication fork collapse and ultimately cell death [11, 12].